Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug 1;107(8):1955-1959.
doi: 10.3324/haematol.2021.280289.

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Sabina Chiaretti  1 , Massimiliano Bonifacio  2 , Roberta Agrippino  3 , Fabio Giglio  4 , Mario Annunziata  5 , Antonio Curti  6 , Maria Ilaria Del Principe  7 , Prassede Salutari  8 , Mariarita Sciumè  9 , Mario Delia  10 , Marco Armenio  11 , Valentina Mancini  12 , Antonino Mulè  13 , Francesco Grimaldi  14 , Giovanna Rege-Cambrin  15 , Lidia Santoro  16 , Federico Lussana  17 , Patrizia Chiusolo  18 , Crescenza Pasciolla  19 , Anna Maria Scattolin  20 , Marco Cerrano  21 , Maria Ciccone  22 , Marzia Defina  23 , Fabio Forghieri  24 , Carla Mazzone  25 , Matteo Piccini  26 , Felicetto Ferrara  5 , Giovanni Pizzolo  2 , Robin Foà  3
Affiliations

COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report

Sabina Chiaretti et al. Haematologica. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Incidence and distribution of COVID-19, and treatment interruption in patients with acute lymphoblastic leukemia. (A) Percentages of patients with acute lymphoblastic leukemia (ALL) with or without COVID-19. (B) Geographical distribution of infected cases, together with percentages in relation to the geographical area. (C) Distribution of infected cases according to period. (D) Treatment interruption according to the type of ALL.
See this image and copyright information in PMC

References

    1. Lee LYW, Cazier JB, Starkey T, et al. . Coronavirus Cancer Monitoring Project Team. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study. Lancet Oncol. 2020;21(10):1309-1316. - PMC - PubMed
    1. Passamonti F, Cattaneo C, Arcaini L, et al. ; ITA-HEMA-COV Investigators. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745. - PMC - PubMed
    1. Girmenia C, Gentile G, Micozzi A, et al. . COVID-19 in patients with hematologic disorders undergoing therapy: perspective of a large referral hematology center in Rome. Acta Haematol. 2020;143(6):574-582. - PubMed
    1. Wu Y, Lin H, Xie Q, Chen Q, Huang Y, Zhu Y, Chen L. COVID-19 in a patient with pre-existing acute lymphoblastic leukaemia. Br J Haematol. 2020;190(1):e13-e15. - PMC - PubMed
    1. Butt A, Ali N. COVID-19 and adult acute lymphoblastic leukemia: presentation and management. Hematol Transfus Cell Ther. 2021;43(2):219-221. - PMC - PubMed

MeSH terms